EssilorLuxottica (OTCMKTS:ESLOY) Reaches New 52-Week Low - Time to Sell?

Key Points

• EssilorLuxottica hit a new 52-week low of $108.3850 (last $109.15) and was trading down about 1.8%, remaining well below its 50-day ($121.83) and 200-day ($151.75) moving averages.
• Analysts are still broadly positive with an average rating of Buy, including recent upgrades from HSBC and Kepler and a consensus made up of two Strong Buy, five Buy and one Hold.
• The company shows low leverage (debt-to-equity 0.17) but relatively tight liquidity (quick ratio 0.70, current ratio 0.99), suggesting strong balance-sheet conservatism alongside near-par short-term coverage.

EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY - Get Free Report) reached a new 52-week low during trading on Saturday . The company traded as low as $108.3850 and last traded at $109.15, with a volume of 155680 shares trading hands. The stock had previously closed at $111.19.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. HSBC raised shares of EssilorLuxottica from a "hold" rating to a "buy" rating in a research report on Wednesday, January 14th. Kepler Capital Markets upgraded EssilorLuxottica from a "hold" rating to a "buy" rating in a research note on Thursday, January 15th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy".

EssilorLuxottica Trading Down 1.8%

The company has a 50 day moving average of $121.83 and a 200-day moving average of $151.75. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.70 and a current ratio of 0.99.

EssilorLuxottica Company Profile

EssilorLuxottica SE is a global ophthalmic optics company formed through the 2018 merger of France-based Essilor and Italy-based Luxottica. Headquartered near Paris, the company combines lens manufacturing, frame design and production, brand management and retail operations to provide a vertically integrated offering across the vision care value chain. Its activities span product research and development, manufacturing, wholesale distribution and retailing of spectacles, sunglasses and ophthalmic lenses.

The company's product portfolio includes prescription and non-prescription lenses, lens coatings and treatments, and an array of eyewear brands and frames.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.